Title: Evaluation of fixed dose four-factor prothrombin complex concentrate for warfarin reversal at a level 1 trauma center
Abstract: FDA-approved dosing of four-factor prothrombin complex concentrate (4F-PCC) in the USA is based on an INR and weight; however, there are data suggesting that a fixed dose of 4F-PCC may be sufficient for INR reversal and hemostasis [1,2]. The objective of this study was to assess the efficacy and safety of a fixed dose of 1,500 units of 4F-PCC. Historically, warfarin reversal included a combination of factor IX complex, vitamin K, and fresh frozen plasma (FFP). Using a fixed dose of 4F-PCC may also provide significant cost savings when compared with traditional dosing.